Samay

Executive Summary

Samay is a San Francisco-based digital health company founded in 2020 that leverages AI and machine learning to deliver personalized care and chronic disease management solutions. Its platform uses data-driven insights to create tailored health interventions and remote monitoring tools, aiming to improve patient outcomes while reducing healthcare costs. By targeting chronic conditions such as diabetes, hypertension, and heart disease, Samay addresses a massive and growing market where personalized, scalable interventions are urgently needed. The company's technology has the potential to streamline care delivery and enhance patient engagement, positioning it as a promising player in the digital health space. Despite operating in a competitive landscape, Samay's focus on AI-driven personalization and its early-stage foundation suggest significant upside if it can secure strategic partnerships and funding to scale. The company currently lacks disclosed revenue or funding details, indicating it may be pre-revenue or in stealth mode. Key near-term catalysts include fundraising, product launches, or validation through clinical studies. If successful, Samay could become an attractive acquisition target for larger healthcare or technology firms looking to expand into AI-powered chronic care. However, execution risk remains elevated given the absence of public performance metrics.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round Close70% success
• Q4 2026Partnership with Major Health System for Pilot Deployment60% success
• Q3 2026Launch of New AI-Driven Remote Monitoring Module65% success